Focus: Corbus Pharmaceuticals is a specialty pharma company focused on orphan inflammatory-fibrotic diseases with a pipeline spanning immunology, neurology, and rare diseases. The company operates at modest scale with 4 active job openings and a Massachusetts headquarters.
Profile data last refreshed 56m ago · AI intelligence enriched 2mo ago
Best suited for early-career professionals seeking rare disease expertise and clinical trial exposure in a high-risk, early-stage environment with modest near-term catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Corbus Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Corbus Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
HPV-linked throat and cervical cancer drug shrinks tumors in early trial - Stock Titan
HPV-linked throat and cervical cancer drug shrinks tumors in early trial Stock Titan
Corbus Pharmaceuticals (CRBP) Slides 1.4% as Key Support Level Comes into Focus - ADD Alert - Newser
Corbus Pharmaceuticals (CRBP) Slides 1.4% as Key Support Level Comes into Focus - ADD Alert Newser
Former Evercore MD joins Corbus ahead of ASCO cancer drug data - Stock Titan
Former Evercore MD joins Corbus ahead of ASCO cancer drug data Stock Titan
Corbus Pharmaceuticals stock (US21833E1038): cancer pipeline update keeps investors watching - AD HOC NEWS
Corbus Pharmaceuticals stock (US21833E1038): cancer pipeline update keeps investors watching AD HOC NEWS
Corbus Pharmaceuticals appoints pharma industry veteran Brent Pfeiffenberger to board of directors - marketscreener.com
Corbus Pharmaceuticals appoints pharma industry veteran Brent Pfeiffenberger to board of directors marketscreener.com
Corbus Pharmaceuticals (NASDAQ: CRBP) adds industry veteran to board and expands 2024 equity plan - Stock Titan
Corbus Pharmaceuticals (NASDAQ: CRBP) adds industry veteran to board and expands 2024 equity plan Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo